Schaupp et al. demonstrated that ETI treatment over 12 months resulted in decreases in proteases, free NE activity, CatG and PR3 and P. aeruginosa levels in CF sputum but without eliminating NSP activity in this group [97]. The gene discussed is ELANE; the disease is cystic fibrosis.